Donanemab

Donanemab (LY3002813) is a humanized IgG1 monoclonal antibody directed at an N-terminal pyroglutamate amyloid beta (Aβ) epitope. Donanemab has the potential for early Alzheimer's disease research[1][2].

Product Specifications

CAS Number

[1931944-80-7]

Product Name Alternative

LY3002813

UNSPSC

12352203

Target

Amyloid-β

Type

Inhibitory Antibodies

Related Pathways

Neuronal Signaling

Applications

Neuroscience-Neurodegeneration

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/donanemab.html

Purity

99.19

Solubility

10 mM in DMSO

Smiles

[Donanemab]

Molecular Weight

(145.36 kDa)

References & Citations

[1]Stephen Loucian Lowe, et al. Donanemab (LY3002813) dose-escalation study in Alzheimer's disease. Alzheimers Dement (N Y) . 2021 Feb 14;7 (1) :e12112.|[2]Mark A Mintun, et al. Donanemab in Early Alzheimer's Disease. N Engl J Med. 2021 May 6;384 (18) :1691-1704.